Migraine with brainstem aura …

Chun-Pai Yang MD PhD

Headache & Pain

Updated 03.31.2024
Released 09.02.1994
Expires For CME 03.31.2027

Migraine with brainstem aura

Author: Chun-Pai Yang MD PhD

See Contributor Disclosures

Editor: Shuu-Jiun Wang MD

Migraine with brainstem aura

In This Article

Quick Link

Introduction

Overview

In response to advances in research and treatment, an evolving International Classification of Headache Disorders (ICHD) system is available for physicians to properly diagnose headache disorders. What was formerly known as “basilar-type migraine,” “basilar migraine,” “basilar artery migraine,” or “Bickerstaff migraine” is now referred to as migraine with brainstem aura. Because the involvement of the basilar artery is unlikely, the term “migraine with brainstem aura” is preferred. The associated symptoms clearly originate from the brainstem and are not ischemic in etiology. According to the ICHD-3, the diagnosis of migraine with brainstem aura is basically clinical on the findings of full reversible speech or language, sensory, or visual auras that are not accompanied by retinal or motors symptoms. There must be at least two of the following “brainstem” symptoms present: dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia not attributable to sensory deficit, and decreased level consciousness (Glasgow Coma Scale ≤13). By definition, the aura symptoms spread over 5 or more minutes, last from 5 to 60 minutes, and may be followed by a headache within 1 hour. Some authors have proposed requiring three rather than the current criteria of two brainstem aura symptoms for diagnosis, while setting a more stringent criterion of combining hearing loss and tinnitus into a single auditory feature, criterion B ("hearing loss and/or tinnitus") (83; 52). Otherwise, a patient with vestibular migraine and vertigo attacks could easily meet the diagnosis of migraine with brainstem aura when the patient also has hearing loss and tinnitus onset. Although migraine with brainstem aura is a rare subtype of migraine, it occurs in 1.5% of patients with headache and 6.6% to 10% of migraine with aura. The onset of the disease usually occurs at the second or third decade. The differential diagnosis for this disorder includes any condition that can cause symptoms and signs referable to posterior circulation insufficiency, including transient ischemic attack, vertebral dissection, or thrombosis. Furthermore, seizures, CADASIL, MELAS, and the posterior fossa vascular and congenital abnormalities, including arteriovenous malformations, Chiari malformations, cavernous angioma, or platybasia, may need to be excluded by MRI. Despite the lack of data suggesting migraine with brainstem aura as a vasospastic condition, the use of triptans has been considered prohibited. Anticonvulsants and calcium channel blockers may be the drugs of choice in the prophylaxis.

Key points

	• Migraine with brainstem aura is an episodic disorder and occurs in 1.5% of patients with headache and 6.6% to 10% of migraine with aura.
	• Migraine with brainstem aura is a variant of migraine with the aura symptoms arising from the brainstem or bilateral occipital hemispheres.
	• “Basilar-type migraine” has been renamed “migraine with brainstem aura” according to ICHD-3.
	• The onset of the disease usually occurs at the second or third decade.
	• The diagnosis is based on the finding of at least two migraine attacks accompanied by at least two of the following fully reversible symptoms: dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia not attributable to sensory deficit, and decreased level consciousness (Glasgow Coma Scale ≤13).
	• The aura symptoms clearly originate from the brainstem without motor weakness.
	• The differential diagnosis should include cerebrovascular diseases, seizures, CADASIL, MELAS, and the pathology of posterior fossa.
	• Despite the lack of data suggesting migraine with brainstem aura as a vasospastic condition, the use of triptans has been considered prohibited.
	•Due to the lack of cardiovascular risks of these new classes of migraine-specific treatments, such as targeting 5-HT1F receptors (lasmiditan) and calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), they may be used to relieve the acute symptoms of individuals with migraine with brainstem aura.
	• Anticonvulsants and calcium channel blockers may be the drugs of choice in the prophylactic treatments.
	• Although no research specifically addresses the treatment of migraine with brainstem aura, CGRP-targeted therapy (gepants, anti-CGRP mAbs) may be the most promising for future consideration.

Historical note and terminology

In 1961, Bickerstaff was the first to propose the concept of “basilar artery migraine” (09). He found two patients with identical symptoms that were only explicable on the basis of an abnormality of basilar artery circulation (11). One of these cases involved a 14-year-old whose symptoms lasted a few hours and were repeated on numerous occasions. The other involved an elderly man whose symptoms progressed rapidly to coma and death, and thrombotic occlusion of the basilar artery with infarction in brainstem and occipital cortex was demonstrated at autopsy. It was by clinical analogy with the structural lesion in the basilar artery and the symptoms of basilar artery territory ischemia that the syndrome “basilar artery migraine” was first described.

Bickerstaff attributed the earliest recorded description of basilar artery migraine to Aretaeus, who gave the following description in the first century AD:

If darkness possess the eye, and if the head be whirled round with dizziness, and the ears ring as from the sound of rivers rolling along with a great noise, or like the wind when it roars among the sails, or like the clang of pipes or reeds, or like the rattling of a carriage, we call the affection scotoma (or vertigo). The mode of vertigo is heaviness of the head, sparkles of light in the eyes along with much darkness, ignorance of themselves and those around, and if the disease go on increasing, the limbs sink below them and they crawl on the ground; there is nausea and vomiting of phlegm or of yellow or black bilious matter... (12).

Gowers probably provided the first case history of migraine with brainstem aura in the medical literature (35). A female patient began to have right-sided migrainous attacks at the age of 18 years. 10 years later, these attacks changed, and she began to lose the sight in both eyes (“a black curtain seemed to be dropped down, brilliant with thousands of golden points”); she then experienced severe vertigo and dysesthesia in the arms, legs, and jaw, all lasting 10 minutes. Next, she became truly unconscious for 15 minutes and then recovered with severe headache spreading from the mastoids over the occipital region, which lasted for 2 hours.

The International Headache Society reclassified this disorder as basilar-type migraine in 2004 to replace the terminology of “basilar artery migraine,” “basilar migraine,” “Bickerstaff migraine,” and “syncopal migraine,” because involvement of the basilar artery territory is uncertain (Headache Classification Committee of the International Headache Society 2004). The diagnostic criteria are similar to those for migraine with aura, except that the aura symptoms clearly originate from the brainstem or bilateral occipital lobes. The symptom of “bilateral paresis” was eliminated from the criteria, in order to separate this disorder from hemiplegic migraine.

In 2013, the International Headache Society reclassified this disorder as migraine with brainstem aura to replace the terminology of “basilar-type migraine” (38). Following ICHD-3 beta, ICHD-3 is published in 2018, and the diagnostic criteria for migraine with brainstem aura are as follows (Table 1).

Table 1. Diagnostic Criteria of Migraine with Brainstem Aura (ICHD-3)

	(1) Attacks fulfilling criteria for 1.2. migraine with aura and criterion B below (2) Aura with both of the following: (3) At least two of the following fully reversible brainstem symptoms:
		(A) dysarthria (B) vertigo (C) tinnitus (D) hypacusis (E) diplopia (F) ataxia not attributable to sensory deficit (G) decreased level of consciousness (GCS ≤13)
	(4) No motor or retinal symptoms
Notes 1. Dysarthria should be distinguished from aphasia. 2. Vertigo does not embrace and should be distinguished from dizziness. 3. This criterion is not fulfilled by sensations of ear fullness. 4. Diplopia does not embrace (or exclude) blurred vision. 5. The Glasgow Coma Scale (GCS) score may have been assessed during admission; alternatively, deficits clearly described by the patient allow GCS estimation. 6. When motor symptoms are present, code as 1.2.3 hemiplegic migraine. (39)

Clinical manifestations

Presentation and course

Migraine with brainstem aura is an episodic disorder and occurs in 1.5% of patients with headache (84). More than one third of subjects have their first attack in the second decade of life, and two thirds in the second or third decade (71). The condition also occurs frequently in children (40), and a small number of cases may present for the first time after age 50. The condition may occur in combination with other types of migraine, but migraine with brainstem aura remains the dominant form in more than 75% of cases (71). At first, Bickerstaff noted predominance of teenage girls in his basilar artery migraine population, but subsequent experience revealed a female incidence similar to other types of migraine (09). The highest female-to-male ratio (approximately 3:1) is found when migraine with brainstem aura first presents in the second decade of life (71). Not uncommonly, when basilar artery migraine begins in the teens, the frequency of attacks diminishes in adult life and is replaced by other forms of migraine (10; 12).

Patients who suffer from migraine with brainstem aura identify precipitating factors similar to those of other forms of migraine. Precipitating factors were identified by 71% of subjects in one series (71). Intense emotional stimuli (74%) and sleep disorders (65%) were the most common trigger factors, followed by change in weather, sunshine, cold wind, acute stress, alcohol, and fatigue (84).

Migraine with brainstem aura occurred in 23 of 348 patients (6.6%) with migraine with nonhemiplegic aura. Mean age at onset was 20.3 ± 11.7 years (range 6 to 49 years). Among these patients, 15 of 23 patients (65%) reported bilateral pain, and 8 of 23 patients (35%) reported unilateral pain. The basilar-type aura comprised diplopia (52%), vertigo (43%), tinnitus (43%), bilateral visual symptoms (39%), hypacusia (26%), ataxia (26%), dysarthria (22%), bilateral paresthesias (13%), and decreased level of consciousness (13%) (84).

The aura lasts from 5 minutes to 60 minutes in the majority of cases, but it can extend up to 3 days. Visual symptoms commonly occur first, predominantly in the temporal and nasal fields of vision. The visual disturbance may consist of blurred vision, teichopsia, scintillating scotoma, and graying or total loss of vision. The features may start in one visual field and then spread to become bilateral. Hallucinations of body magnification, especially that of the head and hands corresponding to the dominance of these regions in the sensory cerebral cortex, are also seen (66). Bickerstaff pointed out that when vision is not completely obscured, diplopia might occur, usually as a sixth nerve weakness (12). Some forms of diplopia may appear in as many as 16% of cases (71). Visual symptoms are typically followed by bilateral paresthesias of arms and legs and are frequently associated with a combination of the aforementioned “brainstem symptoms” (13).

Tingling and numbness occur in more than 60% of cases in a typical cheiro-oral spreading pattern seen in migraine with aura. This condition is usually bilateral and symmetrical but may alternate sides in a hemi-distribution pattern. Occasionally, dysesthesia will extend to the trunk.

Vertigo is the most common brainstem symptom, occurring in 61% to 63% of patients (71; 45). Higher frequencies of vertigo attacks, neurologic symptoms, and saccadic dysmetria occurred in patients with migraine with brainstem aura as compared to those with migrainous vertigo (78). The ataxia and tinnitus may accompany or be independent of vertigo. Dysarthria is as frequent as vertigo.

Impairment of consciousness is common (71). Patients may enter into a state of impaired consciousness that resembles sleep from which they may be easily aroused by stimulation, only to return to the same state (10). Rarely, this progresses to stupor and prolonged coma (51; 28; 56). Other forms of altered consciousness include amnesia, syncope, and drop attacks with transient loss of consciousness.

Seizures have been observed in association with migraine with brainstem aura (11; 07). EEG changes without clinical seizures during attacks of typical basilar artery migraine have also been described (48), and these cases are said to have a good response to anticonvulsants (48; 15; 49; 72). De Romanis and colleagues did a long-term follow-up study in seven children with migraine with brainstem aura who had EEG findings of occipital spike-wave complexes and found that the EEG normalized once the migraine with brainstem aura resolved (24). Three of his patients developed seizures, and four developed migraine with aura.

Migraine with brainstem aura associated with conversion symptoms (abnormal movements, pseudo-epileptic fits, or motor, sensation, or sensory deficits) was also reported, and shaking was the most common symptom (58.1%) (31).

Migrainous stroke in a 56-year-old man has been reported (58). He presented with symptoms of a left cerebellar infarct and underwent a thorough evaluation for all possible causes, and none were found. He had an NIH Stroke Scale score of 3 on hospital admission that was reduced to a score of 1 on follow-up 3 months later. Interestingly, his migraines in the left occipital region decreased in frequency (from two per month to one per year) and severity (from 6 or 7 out of 10, to 2 out of 10) after stroke. This may be due to the impairment of vasodilatory responses of the cerebral arteries after a stroke.

In most patients, headache is located in the occipital region. The headache is of a throbbing, pounding nature and is accompanied by severe nausea and vomiting. It is unusual for the headache to be unilateral or localized to the more anterior parts of the cranium. Photophobia and phonophobia occur in one third to one half of the patients. As with other forms of migraine, the symptoms may occur without headache, but this is seen in no more than 4% of cases (71).

Whether migraine with brainstem aura is an independent disease or only a specific form of migraine with typical aura has been explored. In one study, the clinical features of 38 patients with migraine with brainstem aura were analyzed (45). The median duration of aura was 60 minutes (range of 2 minutes to 72 hours), and symptoms included vertigo (61%), dysarthria (53%), tinnitus (45%), diplopia (45%), bilateral visual symptoms (40%), bilateral paresthesias (24%), decreased level of consciousness (21%), hypacusia (21%), and ataxia (5%). Besides the basilar-type aura, all patients described visual aura symptoms during the attacks of migraine with brainstem aura, 61% had a unilateral or bilateral sensory aura, and 40% had aphasic aura. Overall, 95% of the patients with migraine with brainstem aura (36 out of 38) also reported attacks of migraine with typical aura at other times. The study concluded that there was no firm evidence to establish migraine with brainstem aura as an independent disease.

One study suggests that any symptom of so-called brainstem aura may have a cortical origin based on the latest data from functional mapping and clinical observation studies (22). Vertigo, tinnitus or hypacusis, diplopia, dysarthria, and ataxia can originate from a vestibular cortex, auditory cortex, parieto-occipital, precentral gyri, and parietal lobe, respectively. Alteration of consciousness can reflect abnormal neural activation within specific consciousness networks including posterior parietal or prefrontal and cortices. This hypothesis would probably explain the co-occurrence of typical and brain-stem aura during attacks, and these two types of aura fit clinical consequence of a transient cortical dysfunction caused by a cortical spreading depression. The authors further propose that migraine with brainstem aura should be classified as one kind of typical migraine aura.

In addition to brainstem aura, symptoms may originate within the cortex; Yamani and colleagues analyzed all patients with migraine with brainstem aura from the Danish Headache Center (DHC) and a large sample of telephone-interviewed patients with migraine with aura (83). The telephone-interviewed cohort included 1781 subjects with a diagnosis of migraine with aura or probable migraine with aura. Of these, 228 fulfilled the diagnostic criteria for migraine with brainstem aura of the ICHD-3. However, after the face-to-face interview, neurologic examination, and imaging studies, 4 of 293 cases with migraine with brainstem aura (1.37%) were found, corresponding to 0.04% of the general population. They concluded that telephone interview based on the ICHD-3 diagnostic criteria for migraine with brainstem aura is too open and suggested developing tighter criteria of a core syndrome caused by brainstem dysfunction.

Prognosis and complications

The prognosis for migraine with brainstem aura is generally good. Most frequently, patients had their first attacks between the ages of 11 and 20 years (84). The disorder declines in frequency as the patients enter their 20s and 30s. One study demonstrated the favorable long-term outcome of migraine with brainstem aura in children or adolescence: the headache remission rate was 38.5% in migraine with brainstem aura, compared to 23.4% of all patients with migraine with aura (74).

Rarely, migraine with brainstem aura is complicated by stroke, most often in the posterior cerebral artery (12; 80) but also other terminal arteries (69). Migraine is associated with cardiovascular risk factors, and the risk of stroke is increased at least twofold in those with migraine with aura, smoking habit, and oral contraceptive use (27; 47; 70). However, there is no evidence that patients with migraine with brainstem aura have higher risk of stroke than patients with migraine with typical aura. Nevertheless, one case report showed a patient who developed ventricular tachycardia during migraine with brainstem aura attack, which is believed to be related to autonomic dysregulation (65).

Clinical vignette

A 33-year-old, right-handed Caucasian female presented with a history of headaches that began at 18 years of age and were accompanied by spells of visual disturbances and syncope. The headaches improved when the patient was pregnant, but in the postnatal period her visual symptoms and syncope became worse. The headaches were mostly in the left occipital, frontal, and periorbital regions and were reported to be throbbing, accompanied by nausea and vomiting, and lasting as long as 3 days. About an hour prior to the onset of the headaches, the patient would get visual auras consisting of zigzag lines, blurry vision, tunnel vision, left hemianopsia, and palinopsia; the auras would last up to 15 minutes. About once a week, she would have a syncopal spell with loss of consciousness for up to 5 minutes that may or may not have been followed by a headache. EEG, MRI, and MRA were performed and were all normal. She was started on verapamil, and her syncopal episodes promptly ceased. However, she continued to have visual auras, and her headaches increased in frequency. The dose of verapamil was increased, but this caused her to have expressive and receptive aphasic spells. She also experienced blindness and vertigo; these symptoms lasted up to 10 minutes. The dose of verapamil was then reduced, and she was put on lamotrigine and coenzyme Q10; her visual auras and vertigo ceased, and she did not have further aphasic episodes.

Biological basis

Etiology and pathogenesis

Migraine with brainstem aura is considered a variant of migraine, with the aura symptoms arising from the brainstem or bilateral occipital hemispheres.

Genetics. There were reports that migraine with brainstem aura could be associated with CACNA1A non-sense mutation at codon position 583 (67) and ATA1A2 gene (R548H) (03). However, no causative mutations of these two genes were identified in three other reports (45; 19; 21).

Migraine is currently considered a neurovascular disorder related to primary dysfunction of brainstem nuclei involved in nociceptive modulation. The pain of migraine probably arises from complex interactions of (1) the pain-sensitive cranial blood vessels, (2) the trigeminal nerve fibers that innervate them, and (3) the cranial parasympathetic outflow (34). Neurogenic inflammation, produced by the antidromic release of neuropeptides by trigeminal nerve endings, induces the vasodilatation and extravasation of plasma proteins, as well as the sensitization of trigeminal nociceptive nerve endings. Cytokines and chemokines play a role in migraine pain as mediators in neurovascular inflammation and activators of the trigeminal nerve (29).

The brainstem nuclei of the locus ceruleus, the dorsal raphe nuclei, and the periaqueductal gray may be important to the pathogenesis of migraine in general and migraine with brainstem aura in particular. These nuclei regulate cerebral blood flow, influence cortical neuron excitability, and modulate endogenous pain control mechanisms. PET scans taken during acute migraine attacks have demonstrated that brainstem structures are important in the genesis of migraine. These scans have consistently shown increased activation (indicating increases in regional cerebral blood flow values) in median brainstem structures (including periaqueductal gray, midbrain reticular formation, dorsal raphe nuclei, and locus ceruleus) contralateral to the headache side (79; 05). Stimulation of the locus ceruleus reduces cerebral blood flow while causing extracerebral vasodilatation. It is possible that activation of the locus ceruleus causes a vasoconstriction of the basilar artery resulting in brainstem symptoms typical for migraine with brainstem aura, but further studies are needed.

A study with vestibular evoked myogenic potential (VEMP) testing evaluated the sacculo-collic reflex in 20 patients with basilar artery migraine. Absent or delayed VEMPs were detected in some of them, suggesting the descending pathway from the saccule through the brainstem to cranial nerve XI is interrupted, which the authors attributed to hypoperfusion in the territory of the basilar artery. After relief of headache and vertigo following 3 months of medication, 10 asymptomatic patients with either absent or delayed VEMPs before treatment underwent follow-up VEMP testing, and nine of the patients (90%) displayed normal VEMPs bilaterally, suggesting reversible ischemia in the territory of the basilar artery (57).

Vass and colleagues proposed that inner ear symptoms like phonophobia, tinnitus, fluctuation in hearing perception, and increased noise sensitivity provide indirect evidence that cochlear blood vessels are also affected by basilar artery migraine. They examined neuronally mediated permeability changes in the cochlea and basilar artery by colloidal silver and Evans Blue extravasation, following orthodromic and antidromic stimulation of the trigeminal ganglion innervating the cochlea. Capsaicin and electrical stimulation induced both dose- and time-dependent plasma extravasation of colloidal silver and Evans Blue from the basilar artery and anterior inferior cerebellar artery. Both orthodromic and antidromic activation of trigeminal sensory fibers also induced cochlear vascular permeability changes and significant quantitative differences between the treated and control groups in spectrophotometric assays. These results characterize a vasoactive connection between the cochlea and vertebrobasilar system through the trigeminal sensory neurons. Thus, they proposed that vertigo, tinnitus, and hearing deficits associated with migraine with brainstem aura could arise by excitation of the trigeminal nerve fibers in the cochlea, resulting in local plasma extravasation. In addition, cochlear “dysfunction” may also trigger basilar and cluster headache by afferent input to the trigeminal system (77).

Lodi and colleagues studied 78 patients with migraine in attack-free periods, of whom 37 had migraine with typical aura or migraine with brainstem aura, and found that in the occipital lobes of all subgroups of migraine, cytosolic free Mg2+ as well as the free energy released by the reaction of ATP hydrolysis were significantly reduced (59). Among patients with migraine, the level of free energy released by the reaction of ATP hydrolysis and the cytosolic free Mg2+ showed a trend in keeping with the severity of clinical phenotype, both showing the lowest values in patients with migraine stroke and the highest in patients with migraine without aura. These suggest that the reduction in free Mg2+ in tissues with mitochondrial dysfunction is secondary to the bioenergetics deficit and are against a primary role of low brain cytosolic free Mg2+ in causing the bioenergetics deficit in headache. There may, therefore, be little role for magnesium supplementation as a treatment modality in these patients.

One study with stimulation single-fiber EMG on a group of migraineurs revealed that single-fiber EMG abnormalities were almost exclusively seen in patients with migraine with aura, especially if they had prolonged auras or multiple aura types (04). As single-fiber EMG abnormalities are also seen in patients with familial hemiplegic migraine, they postulate that the CACNA1A gene may also be involved in common forms of migraine with aura with resulting P/Q calcium channel dysfunction.

Differential diagnosis

The differential diagnoses of migraine with brainstem aura include cerebrovascular diseases, seizure, and hereditary disorders. The accuracy of the clinical diagnosis can be significantly improved by carefully considering the symptoms that present, the timeline of their course, their relationship to other symptoms, and by actively looking for potential causes (61).

Cerebrovascular diseases are the most serious differential diagnosis of migraine with brainstem aura (63). Transient ischemic attacks involving any part of the vertebrobasilar territory must be considered, particularly if migraine with brainstem aura presents for the first time in the later life. The features of posterior cerebral artery ischemia include photopsia with single and formed visual hallucinations, hemianopic visual loss, transient numbness, episodic light-headedness, confusional spells, tinnitus, and headache (11; 30; 80). Thus, posterior cerebral artery ischemia alone can mimic migraine with brainstem aura. Patients with primary brainstem hemorrhage or subarachnoid hemorrhage commonly present with headache and neurologic deficits, but these will rarely figure into the differential diagnosis unless the symptoms are presenting for the first time. Cerebral arteriovenous malformations of the occipital cortex may present with attacks of migraine with visual aura, complicated by seizures and brainstem neurologic deficits (46). Antiphospholipid antibody syndrome (53) and thrombotic thrombocytopenic purpura can present with transient ischemic attacks and headache.

Episodic seizures, particularly of temporal lobe origin, must be considered in the differential diagnosis of migraine with brainstem aura because of similar symptoms, eg, vertigo, imbalance, confusion, memory disturbance, disorders of consciousness, visual symptoms, and postictal headache (32). However, the visual aura of migraine develops slowly, within minutes, consisting of mainly achromatic and linear patterns, whereas the visual aura of occipital lobe seizure (idiopathic childhood occipital epilepsy of Gastaut) is short-lasting bright colors and circular shapes (62). On the contrary, migraine and seizure are common conditions, and a patient may have both migraine and seizure simultaneously.

Hereditary disorders that present with neurologic deficits similar to attacks of migraine with brainstem aura include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mitochondrial encephalopathy with lactic acidosis and stroke (MELAS). CADASIL is an adult-onset inherited disease due to mutations in the Notch3 gene on chromosome 19p13. Recurrent attacks of severe migrainous headaches with aura, which include transient hemiparesis and brainstem symptoms, have been seen in patients with CADASIL (08; 76). MELAS is associated with several mutations in mitochondrial DNA. Multi-system involvement, lactic acidosis, and recurrent episodes of headache (mostly migraine) are part of the clinical spectrum (26).

Other disorders that may feature in the differential diagnosis include alternating hemiplegia of childhood, meningoencephalitis (86), neoplasia, compressive lesions of the cervicomedullary junction, multiple sclerosis, and Kleine-Levin syndrome (60).

Criteria based on the International Classification of Headache Disorders (ICHD-3) beta-version for 1.2 migraine with aura (MA), 1.2.1 migraine with typical aura (MTA), 1.2.3 hemiplegic migraine, 1.2.2 migraine with brainstem aura, and the alternative criteria A1.2 migraine with aura and A1.2.1 migraine with typical aura according to ICHD-2 were field tested in a cross-sectional study. This study showed that too many patients fulfilled ICHD-2 and ICHD-3 beta criteria for 1.2.2 migraine with brainstem aura, and it suggests that the criteria for 1.2.2 migraine with brainstem aura should be more restrictive (55).

Diagnostic workup

There are no specific diagnostic tests for migraine with brainstem aura. The methods of investigation depend on the clinical characteristics and findings. The patient history and the physical and neurologic examinations are the most important tools for diagnosing migraine with brainstem aura. Blood tests may include a complete blood count (to exclude anemia, polycythemia, and platelet dysfunction), electrolytes, drug screen, lactate, erythrocyte sedimentation rate, antiphospholipid antibody panel, and special coagulation profiles. EEG abnormalities are detected in less than one fifth of cases with migraine with brainstem aura (44) and are mostly independent of any clinical manifestation of the disorder. Ictal EEG may be indicated for migraine with brainstem aura because it is helpful in the differential diagnosis of impaired consciousness and seizure (68). Brainstem and visual evoked responses are not needed unless a complex differential diagnosis is considered.

The seriousness of the neurologic deficit associated with migraine with brainstem aura and the gravity of the potential differential diagnosis are important reasons for an imaging study. MRI is the image of choice because of its sensitivity to focal ischemic lesions and posterior fossa structures. MRA may be helpful in detecting vasculopathies such as arteriovenous malformations, aneurysms, and arterial dissection. Transcranial Doppler studies can provide noninvasive information on basilar artery function (87; 50). When migraine with brainstem aura is associated with familial disorders in which seizures and stroke may figure (eg, MELAS), muscle biopsy and a lactate exercise test may be indicated.

As a final comment, it seems appropriate to quote Bickerstaff himself on the ideal approach to differential diagnosis. It is prudent to maintain the mindset that this should be a diagnosis of exclusion.

Because the clinical picture produced by basilar artery disturbance can be so varied, it is perhaps a little too easy to include under the diagnosis of basilar artery migraine puzzling transient syndromes within this territory. Basilar artery migraine is a diagnosis which is unprovable and great care is required in labeling a patient with such a diagnosis, which, having been made, might be perpetuated without adequate attempts to further elucidate the cause (12).

Management

Although few randomized, controlled drug trials have been conducted for migraine with brainstem aura, the general principles of pharmacologic treatment of migraine can be applied with modifications. Acute attacks can be treated with analgesics such as aspirin or non-steroidal anti-inflammatory agents (NSAIDs) in combination with an antiemetic drug to improve gastrointestinal absorption. Triptans and ergotamines were excluded in the earlier trials because of potential vasoconstrictive properties and have not been well studied. Their safety profiles remain uncertain due to lack of clinical data, so the packages for all triptans continue to label this restriction. Greater occipital nerve blockade has been used to abort migraine with brainstem aura within minutes (06). If consciousness is persistently impaired or if seizure or coma occurs, hospital admission may be justified. A group of antimigraine drugs targeting 5-hydroxytryptamine1F (5-HT1F) receptors (lasmiditan) and gepants (rimegepant, ubrogepant, and zavegepant), a group of calcitonin gene-related peptide (CGRP) receptor antagonists, have demonstrated efficacy and tolerability for the acute treatment of migraine in either phase 2 or phase 3 randomized clinical trials (41; 82; 23). The lack of cardiovascular risks of these new classes of migraine-specific treatments may be used to relieve the acute symptoms of individuals with migraine with brainstem aura (81).

As for preventive therapy, a more aggressive approach is warranted even if the attacks occur only two to three times a year, because the attacks may be disabling or require hospitalization. All the prophylactic agents for migraine with or without aura could be used for migraine with brainstem aura. Calcium channel blockers such as verapamil and flunarizine are probably the drugs of choice, as both have been shown to be effective in the treatment of familial hemiplegic migraine (36; 85). Another calcium channel blocker, cinnarizine, is safe and effective in reducing both headache and vertigo aspects of migraine plus vertigo among the patients who suffer from either vestibular migraine or migraine with brainstem aura (73). The beta blockers and methysergide may be used with caution due to their potential vasoconstrictive properties (02). The tricyclic antidepressants might be avoided if EEG abnormalities are present, due to their propensity to promote seizure activity. In this circumstance, anticonvulsants such as sodium valproate, topiramate, and lamotrigine would be the drugs of choice. One small placebo-controlled trial confirmed the efficacy and safety of topiramate (25 mg and 100 mg) for prophylaxis of migraine with brainstem aura in children (54). There is also an anecdotal report that three women with a 5-year follow-up and one child with migraine with brainstem aura responded well to lamotrigine (25; 18; 42). Anti-CGRP monoclonal antibodies (CGRP mAbs) are now used for the prevention of migraine; however, limited clinical evidence is available regarding their effectiveness in preventing migraine with aura (16; 01; 17). A study demonstrated that during the 1-year anti-CGRP treatment, there was a decrease in attacks of migraine without aura, but no changes in the frequency of migraine aura attacks were recorded (20). Although no research specifically addresses the treatment of migraine with brainstem aura, CGRP mAbs may be the most promising for future consideration.

References

01: Albanese M, Mercuri NB. Could the new anti-CGRP monoclonal antibodies be effective in migraine aura? Case reports and literature review. J Clin Med 2022;11(5):1228. PMID 35268319
02: Alvarez SJ, Molinsa A, Turon A, Titus F, Codina A. Migraine-infarct in patients treated with beta-blockers. Rev Clin Esp 1993;192:228-30. PMID 8097892
03: Ambrosini A, d’Onofrio M, Grieco GS, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology 2005;65(11):1826-8. PMID 16344534
04: Ambrosini A, Maertens de Noordhout A, Schoenen J. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology 2001;56(8):1038-43. PMID 11320175
05: Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet 2001;357(9261):1016-7. PMID 11293599
06: Baron EP, Tepper SJ, Mays M, Cherian N. Acute treatment of basilar-type migraine with greater occipital nerve blockade. Headache 2010;50(6):1057-9. PMID 20487035
07: Basser LS. The relation of migraine and epilepsy. Brain 1969;92:285-300. PMID 4978139
08: Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 1993;24(1):122-5. PMID 8418535
09: Bickerstaff ER. Basilar artery migraine. Lancet 1961a;1:15-7.
10: Bickerstaff ER. Impairment of consciousness in migraine. Lancet 1961b:2:1057-9. PMID 13868977
11: Bickerstaff ER. The basilar artery and migraine-epilepsy syndrome. Proc R Soc Med 1962;55:167-9. PMID 13868978
12: Bickerstaff ER. Basilar artery migraine. In: Clifford Rose F, editor. Handbook of clinical neurology. Amsterdam: Elsevier Science, 1986:135-40.
13: Blumenfeld AE, Victorio MC, Berenson FR. Complicated migraines. Semin Pediatr Neurol 2016;23(1):18-22. PMID 27017017
14: Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA 2006;295(15):1824-30. PMID 16622144
15: Camfield PR, Metrakos K, Andermann F. Basilar migraine, seizures, and severe epileptiform EEG abnormalities. Neurology 1978;28:584-8. PMID 565890
16: Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019;394(10210):1765-74. PMID 31668411
17: Cohen F, Yuan H, DePoy EMG, Silberstein SD. The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 2022;19(3):922-30. PMID 35426060
18: Cologno D, d'Onofrio F, Castriota O, et al. Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up. Neurol Sci 2013;34 Suppl 1:S165-6. PMID 23695071
19: Cologno D, d’Onofrio F, Esposito T, et al. ATP1A2 gene mutations are not present in two sisters with basilar-type migraine associated with menses. Neurol Sci 2008;29(2):113-5. PMID 18483709
20: Cresta E, Bellotti A, Rinaldi G, Corbelli I, Sarchielli P. Effect of anti-CGRP-targeted therapy on migraine aura: results of an observational case series study. CNS Neurosci Ther 2024;30(2):e14595. PMID 38332541
21: Cuenca-León E, Corominas R, Fernàndez-Castillo N, et al. Genetic analysis of 27 Spanish patients with hemiplegic migraine, basilar-type migraine and childhood periodic syndromes. Cephalalgia 2008;28(10):1039-47. PMID 18644040
22: Demarquay G, Ducros A, Montavont A, Mauguiere F. Migraine with brainstem aura: why not a cortical origin? Cephalalgia 2017;38(10):1687-95. PMID 29073774
23: Deng X, Zhou L, Liang C, et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. J Headache Pain 2024;25(1):16. PMID 38311738
24: De Romanis F, Buzzi MG, Assenza S, Brusa L, Cerbo R. Basilar migraine with electroencephalographic findings of occipital spike-wave complexes: a long-term study in seven children. Cephalalgia 1993;13:192-6. PMID 8358777
25: d’Onofrio F, Cologno D, Petretta V, Casucci G, Bussone G. Basilar-type migraine responsive to lamotrigine: three case reports. Neurol Sci 2007;28 Suppl 2:S239-41. PMID 17508181
26: Dvorkin GS, Andermann F, Carpenter S. Classical migraine, intractable epilepsy, and multiple strokes: a syndrome related to mitochondrial encephalomyopathy. In: Andermann F, Lugaresi E, editors. Migraine and epilepsy. Stoneham (MA): Butterworth, 1987:203-32.
27: Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005;330(7482):63. PMID 15596418
28: Ferguson KS, Robinson SS. Life-threatening migraine. Arch Neurol 1982;39:374-6. PMID 7092615
29: Fidan I, Yuksel S, Ymir T, Irkec C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in the pathophysiology of migraine. J Neuroimmunol 2006;171(1-2):184-8. PMID 16325275
30: Fisher CM. The posterior cerebral artery syndrome. Can J Neurol Sci 1986:13:232-9. PMID 3742339
31: Garcia-Albea E. Migraine associated with conversion symptoms (Babinski's migraine): evaluation of a series of 43 cases [Article in Spanish]. Neurologia 2012;27(3):125-35. PMID 21889233
32: Gastaut H, Zifkin BG. Classification of the epilepsy. J Clin Neurophysiol 1985;2:313-26. PMID 4056019
33: Gil-Gouveia R, Wilkinson PA, Kaube H. Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy. Neurology 2004;63(12):2446-7. PMID 15623730
34: Goadsby PJ. Migraine pathophysiology. Headache 2005;45 Suppl 1:S14-24. PMID 15833086
35: Gowers WR. The borderland of epilepsy. London: Churchill Livingstone, 1907.
36: Greenberg DA. Calcium channel antagonists and the treatment of migraine. Clin Neuropharmacol 1986;9(4):311-28. PMID 2425960
37: Headache Classification Subcommittee of the International Headache Society. The International classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1).
38: Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808. PMID 23771276
39: Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38(1):1-211. PMID 29368949
40: Hockaday JM. Basilar migraine in childhood. Dev Med Child Neurol 1979;21:455-63. PMID 520693
41: Huang P, Yang F, Chang C, Yang C. Targeting the 5-HT and 5-HT receptors for acute migraine treatment. Prog Brain Res 2020;255:99-121. PMID 33008517
42: Inoue Y, Yabe T. Lomerizine therapy for the treatment of benign paroxysmal vertigo of childhood transitioning into atypical basilar migraine: a case report. Exp Ther Med 2013;5(6):1573-5. PMID 23837033
43: Jacobson SL, Redman CW. Basilar migraine with loss of consciousness in pregnancy. Br J Obstet Gynecol 1989;96:494-5. PMID 2751966
44: Jacome DE. EEG features in basilar artery migraine. Headache 1987;27:80-3. PMID 3570765
45: Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 2006;66(6):880-6. PMID 16567706
46: Kupersmith MJ, Vargas ME, Yashar A, et al. Occipital arteriovenous malformations: visual disturbances and presentation. Neurology 1996;46(4):953-7. PMID 8780071
47: Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005;64(6):1020-6. PMID 15781820
48: Lapkin ML, French JH, Golden GS. The EEG in childhood basilar artery migraine. Neurology 1977;27:580-3. PMID 559268
49: Lapkin ML, Golden GS. Basilar artery migraine. Am J Dis Child 1978;132:276-81. PMID 629244
50: La Spina I, Vignati A, Porazzi D. Basilar artery migraine: transcranial Doppler EEG and SPECT from the aura phase to the end. Headache 1997;37(1):43-7. PMID 9046723
51: Lawall JS, Oommen JK. Basilar artery migraine presenting as conversion hysteria. J Nerv Ment Dis 1978;166:809-11. PMID 722303
52: Lempert T, Seemungal BM. How to define migraine with brainstem aura? Brain 2020;143(5):e35. PMID 32282900
53: Levine SR, Joseph R, D’Andrea G, Welch KM. Migraine and the lupus anticoagulant. Cephalalgia 1987;7:93-9. PMID 3111715
54: Lewis D, Paradiso E. A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study. Headache 2007;47(10):1409-17. PMID 18052950
55: Li D, Christensen AF, Olesen J. Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura. Cephalalgia 2015;35(9):748-56. PMID 25424707
56: Li Q, Tan G, Zhou J. Basilar-type migraine with coma: case reports and literature review. Pain Med 2011;12(4):654-6. PMID 21463463
57: Liao LJ, Young YH. Vestibular evoked myogenic potentials in basilar artery migraine. Laryngoscope 2004;114(7):1305-9. PMID 15235366
58: Linetsky E, Leker RR, Ben-Hur T. Headache characteristics in patients after migrainous stroke. Neurology 2001;57(1):130-2. PMID 11445642
59: Lodi R, Iotti S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001;54(4):437-41. PMID 11306197
60: Nesbitt AD, Leschziner GD. Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). Pract Neurol 2016;16(5):402-5. PMID 27343267
61: Pacheva IH, Ivanov IS. Migraine variants--occurrence in pediatric neurology practice. Clin Neurol Neurosurg 2013;115(9):1775-83. PMID 23688445
62: Panayiotopoulos CP, Michael M, Sanders S, Valeta T, Koutroumanidis M. Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. Brain 2008;131(Pt 9):2264-86. PMID 18718967
63: Park JJ, Kim SJ, Kim HY, Roh HG, Kim DW. Migraine with aura as a stroke mimic. Can J Neurol Sci 2020;47(2):242-4. PMID 31657289
64: Pianezza A, Barthélémy R, Minville V, Martin F, Faggianelli M. Migraine with atypical aura in the recovery room: a sometimes complicated diagnosis! Anesth Analg 2008;106(6):1844-6. PMID 18499620
65: Pitarokoili K, Dahlhaus S, Hellwig K, et al. Ventricular tachycardia during basilar-type migraine attack. Ther Adv Neurol Disord 2013;6(1):35-40. PMID 23277791
66: Podoll K, Ebel H. [Hallucinations of body magnification in migraine]. Fortschr Neurol Psychiatr. 1998;66(6):259-70. PMID 9676421
67: Robbins MS, Lipton RB, Laureta EC, Grosberg BM. CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2. Headache 2009;49(7):1042-6. PMID 19486177
68: Sandrini G, Friberg L, Jänig W, et al. Neurophysiological tests and neuroimaging procedures in non-acute headache: guidelines and recommendations. Eur J Neurol 2004;11(4):217-24. PMID 15061822
69: Solomon GD, Spaccavento LJ. Lateral medullary syndrome after basilar migraine. Headache 1982;22:171-2. PMID 7107245
70: Stang PE, Carson AP, Rose KM, et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 2005;64(9):1573-7. PMID 15883318
71: Sturzenegger MH, Meienberg O. Basilar artery migraine: a follow-up study of 82 cases. Headache 1985;25:408-15. PMID 4086291
72: Swanson JW, Vick NA. Basilar artery migraine. Neurology 1978;28:782-6. PMID 567295
73: Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus 2014;3:231. PMID 24834377
74: Termine C, Ferri M, Livetti G, et al. Migraine with aura with onset in childhood and adolescence: Long-term natural history and prognostic factors. Cephalalgia 2010;30(6):674-81. PMID 20511205
75: Thurlow JA. Hemiplegia following general anaesthesia: an unusual presentation of migraine. Eur J Anaesthesiol 1998;15(5):610-2. PMID 9785080
76: Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser MG. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol 2004;61(8):1237-40. PMID 15313840
77: Vass Z, Steyger PS, Hordichok AJ, Trune DR, Jancso G, Nuttall AL. Capsaicin stimulation of the cochlea and electric stimulation of the trigeminal ganglion mediate vascular permeability in cochlear and vertebro-basilar arteries: a potential cause of inner ear dysfunction in headache. Neuroscience 2001;103(1):189-201. PMID 11311800
78: Wang CT, Lai MS, Young YH. Relationship between basilar-type migraine and migrainous vertigo. Headache 2009;49(3):426-34. PMID 19178580
79: Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1(7):658-60. PMID 7585147
80: Welch KM, Levine SR. Migraine-related stroke in the context of the International Headache Society classification of head pain. Arch Neurol 1990;47:458-62. PMID 2181979
81: Xu SY, Li HJ, Huang J, Li XP, Li CX. Migraine with brainstem aura accompanies by disorders of consciousness. J Pain Res 2021;14:1119-27. PMID 33907459
82: Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Network Open 2021;4(10):e2128544. PMID 34633423
83: Yamani N, Chalmer MA, Olesen J. Migraine with brainstem aura: defining the core syndrome. Brain 2019:142(12):3868-75. PMID 31789370
84: Ying G, Fan W, Li N, et al. Clinical characteristics of basilar-type migraine in the neurological clinic of a university hospital. Pain Med 2014;15(7):1230-5. PMID 24666545
85: Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 2003;60(1):120-1. PMID 12525732
86: Zambito Marsala S, Gioulis M. Basilar migraine mistaken for encephalitis. Neurol Sci 2012;33(1):213-4. PMID 21678071
87: Zwetsloot CP, Caekebeke JF, Jansen JC, Odink J, Ferrari MD. Blood flow velocities in the vertebrobasilar system during migraine attacks—a transcranial Doppler study. Cephalalgia 1992;12:29-32. PMID 1559255

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Chun-Pai Yang MD PhD

Dr. Yang of Kuang Tien General Hospital in Taichung, Taiwan, has no relevant financial relationships to disclose.
See Profile

Editor

Shuu-Jiun Wang MD

Dr. Wang of the Brain Research Center, National Yang-Ming University, and the Neurological Institute, Taipei Veterans General Hospital, has no relevant financial relationships to disclose.
See Profile

Former Authors

K Michael A Welch MD
Hua C Siow MD
Shiang-Ru Lu MD
Kai-Chen Wang MD

Patient Profile

Age range of presentation: 13 to 44 years
Sex preponderance: female>male, >2:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Migraine with brainstem aura

Differential Diagnosis

alternating hemiplegia of childhood
antiphospholipid antibody syndrome
basilar artery occlusive disease
cerebral aneurysm
cerebral arteriovenous malformations
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
- cerebrovascular disease
- compressive lesions of the cervicomedullary junction
- ischemic stroke
- Meniere disease
- meningoencephalitis
- mitochondrial encephalopathy with lactic acidosis and stroke
- multiple sclerosis
- neoplasia
- occipital lobe epilepsy
- posterior cerebral artery ischemia
- primary brainstem hemorrhage
- recurrent vertigo
- subarachnoid hemorrhage
- temporal lobe epilepsy
- transient ischemic attacks
- vertebral artery dissection

Also Relevant

Epidemiology of headache
Hemiplegic migraine
Migraine
Migraine and epilepsy
Neuroimaging of headache
- Vertigo

Clinical Categories

Headache & Pain

Patient Handouts

Headache

Web References

Guidelines

AAN: Headache

Migraine with brainstem aura …

Migraine with brainstem aura

Introduction

Overview

Key points

Historical note and terminology

Table 1. Diagnostic Criteria of Migraine with Brainstem Aura (ICHD-3)

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Headache associated with intracranial neoplasms

Acupuncture

Migraine in childhood

Headache attributed to head trauma

Migraine: pathogenesis and pathophysiology

Tension-type headache

Benign paroxysmal vertigo

Vagal nerve stimulation for headaches

Migraine with brainstem aura

Introduction

Overview

Key points

Historical note and terminology

Table 1. Diagnostic Criteria of Migraine with Brainstem Aura (ICHD-3)

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Headache associated with intracranial neoplasms

Acupuncture

Migraine in childhood

Headache attributed to head trauma

Migraine: pathogenesis and pathophysiology

Tension-type headache

Benign paroxysmal vertigo

Vagal nerve stimulation for headaches

This is an article preview.
Start a Free Account
to access the full version.